Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study

Arteriosclerosis Thrombosis and Vascular Biology, Journal Year: 2023, Volume and Issue: 43(3), P. 482 - 491

Published: Feb. 2, 2023

In cross-sectional and retrospective cohort studies, we examined comparative associations between nonalcoholic fatty liver disease (NAFLD) metabolic dysfunction-associated (MAFLD) risk of having or developing coronary artery calcification (CAC). Participants who had health examinations 2010 2019 were analyzed. Liver ultrasonography computed tomography used to diagnose CAC. divided into a MAFLD no-MAFLD group then NAFLD no-NAFLD groups. further no (reference), NAFLD-only, MAFLD-only, both Logistic regression modeling was performed. Cox proportional hazard model examine the incident CAC in participants without at baseline least two measurements. analyses, 162 180 included. Compared with either groups, groups associated higher prevalent (NAFLD: adjusted odds ratio [OR], 1.34 [95% CI, 1.29-1.39]; MAFLD: OR, 1.44 1.39-1.48]). Among 4 MAFLD-only strongest association (adjusted 1.60 1.52-1.69]). Conversely, NAFLD-only lower 0.76 0.66-0.87]). longitudinal 34 233 ratio, 1.68 1.43-1.99]; 1.82 1.56-2.13]). these 2.03,[95% 1.62-2.55]). The not independently 0.88 0.44-1.78]) Conclusions: Both are significantly an increased prevalence incidence These tended be stronger for MAFLD.

Language: Английский

---

Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease

Nature Communications, Journal Year: 2023, Volume and Issue: 14(1)

Published: March 17, 2023

Abstract Polypharmacy is common in patients with nonalcoholic fatty liver disease (NAFLD) and previous reports suggest that NAFLD associated altered drug disposition. This study aims to determine if are at risk for response by characterizing changes hepatic mRNA expression of genes mediating disposition (pharmacogenes) across the histological severity spectrum. We utilize RNA-seq 93 biopsies histologically staged Activity Score (NAS), fibrosis stage, steatohepatitis (NASH). identify 37 significant pharmacogene-NAFLD associations including CYP2C19 downregulation. chose validate due its actionability prescribing. Meta-analysis 16 independent studies demonstrate significantly downregulated 46% NASH, 58% high NAS, 43% severe fibrosis. Our data downregulation which supports developing personalized medicine approaches drugs sensitive metabolism enzyme.

Language: Английский

---

Oxidative balance score is inversely associated with the incidence of non-alcoholic fatty liver disease

Clinical Nutrition, Journal Year: 2023, Volume and Issue: 42(8), P. 1292 - 1300

Published: June 15, 2023

Language: Английский

---

Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives

Nutrients, Journal Year: 2023, Volume and Issue: 15(3), P. 687 - 687

Published: Jan. 29, 2023

While non-alcoholic fatty liver disease (NAFLD) is a prevalent and frequent cause of liver-related morbidity mortality, it also strongly associated with cardiovascular disease-related likely driven by its associations insulin resistance other manifestations metabolic dysregulation. However, few satisfactory pharmacological treatments are available for NAFLD due in part to complex pathophysiology, challenges remain stratifying individual patient’s risk related outcomes. In this review, we describe the development progression NAFLD, including pathophysiology We different tools identifying patients who most at cardiovascular-related complications, as well current emerging treatment options, future directions research.

Language: Английский

---

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk

Nutrients, Journal Year: 2023, Volume and Issue: 15(18), P. 3970 - 3970

Published: Sept. 14, 2023

Metabolism-associated fatty liver disease (MAFLD) is a multifaceted that involves complex interactions between various organs, including the gut and heart. It defined by hepatic lipid accumulation related to metabolic dysfunction, obesity, diabetes. Understanding intricate interplay of gut–liver–heart crosstalk crucial for unraveling complexities MAFLD developing effective treatment prevention strategies. The gut–liver participates in regulation inflammatory processes through host–microbiome interactions. Gut microbiota have been associated with development progression MAFLD, its dysbiosis contributes insulin resistance, inflammation, oxidative stress. Metabolites derived from enter systemic circulation influence both heart, resulting axis playing an important role MAFLD. Furthermore, growing evidence suggests endothelial inflammation may contribute increased risk cardiovascular (CVD). Additionally, dysregulation metabolism also lead cardiac dysfunction heart failure. Overall, molecular pathways CVD patients This review emphasizes current understanding as foundation optimizing patient outcomes

Language: Английский

---